Cooper Companies Surpasses Q2 Expectations with 7% Organic Revenue Growth
The Cooper Companies recently reported its second-quarter earnings for 2025, exceeding expectations with a 7% organic revenue growth. The company's consolidated revenues reached $1.002 billion, a 6% year-over-year increase.
At the helm of CooperVision and CooperSurgical, President and CEO Al White highlighted the successful quarter, citing double-digit growth in both daily silicone hydrogel lenses at CooperVision and office and surgical portfolio at CooperSurgical. Non-GAAP earnings reached $0.96, a 14% year-over-year increase.
CooperVision reported quarterly revenues of $670 million, with growth rates organically reaching 7%. Americas grew by 8%, EMEA by 6%, and Asia Pacific by 5%. Within categories, torics and multifocals showed a 7% growth, while myopia management portfolio experienced an impressive 19% increase.
The MyDay daily silicone hydrogel lenses continue to shine, with double-digit growth driven by strength in torics, multifocals, and innovative Energys offerings. The company remains bullish on this product family, expecting accelerated revenue growth starting in fiscal Q4.
CooperSurgical also saw growth, with quarterly revenues reaching $333 million, an 8% year-over-year increase. Margins improved nicely across the board, a testament to the company's operational improvements and OpEx leverage.
The company continues to execute well, launching new products and expanding capacity while controlling costs in a complex global operating environment. CooperVision is expected to benefit from increased availability of its daily silicone hydrogel lenses in new markets and channels.
Cooper Companies' success can be attributed to its ability to adapt and innovate in response to changing market conditions. As the company looks ahead, it appears poised for continued growth and success in its respective markets.
